This technology is a cell therapy method involving the administration of hematopoietic stem cells to prevent organ rejection in transplant patients.
Current organ transplantation methods often face significant challenges due to the immune system's rejection of the transplanted organ, leading to graft failure. Standard immunosuppressive therapies can reduce the risk of rejection but often come with severe side effects and do not guarantee long-term graft survival. There is a critical need for more effective strategies to promote immune tolerance to the transplanted organ, reducing the risk of rejection and minimizing the dependency on lifelong immunosuppression.
This technology uses a targeted administration of hematopoietic stem cells or CD34+ cells to establish mixed chimerism in organ transplant recipients, reducing the risk of organ rejection by promoting immune tolerance. The cells are carefully selected to minimize T-cell content, lowering the chance of graft-versus-host disease. The approach is supported by additional immunosuppressive agents administered in a controlled timeframe post-transplant. Validation testing has shown that this method significantly improves graft survival rates.
Patent Pending(US20240252541)
IR CU22264
Licensing Contact: [Jerry Kokoshka](mailto:techtransfer@columbia.edu)
